Table 1:
Baseline characteristics
| All patients in NTRK gene fusion-positive efficacy-evaluable population (n=54) | |
|---|---|
| Age, years | 58 (48–67) |
| Sex | |
| Female | 32 (59%) |
| Male | 22 (41%) |
| Race | |
| White | 43 (80%) |
| Asian | 7 (13%) |
| Other | 4 (7%) |
| Eastern Cooperative Oncology Group performance status | |
| 0 | 23 (43%) |
| 1 | 25 (46%) |
| 2 | 6 (11%) |
| Previous lines of systemic therapy | |
| 0 | 20 (37%) |
| 1 | 11 (20%) |
| 2 | 14 (26%) |
| 3 | 4 (7%) |
| ≥4 | 5 (9%) |
| Previous treatment* | |
| Chemotherapy | 46 (85%) |
| Targeted therapy | 13 (24%) |
| Hormonal therapy | 9 (17%) |
| Immunotherapy | 7 (13%) |
| CNS metastases at baseline | |
| Yes | 12 (22%) |
| No | 42 (78%) |
| Previous radiotherapy to the brain | |
| Yes | 7 (13%) |
| No | 47 (87%) |
| Time from end of previous radiotherapy of the brain to first dose of entrectinib† | |
| <2 months | 2 (29%) |
| 2 to <6 months | 4 (57%) |
| ≥6 months | 1 (14%) |
| Tumour type | |
| Sarcoma‡ | 13 (24%) |
| NSCLC | 10 (19%) |
| Mammary analogue secretory carcinoma (salivary) | 7 (13%) |
| Breast | 6 (11%) |
| Thyroid | 5 (9%) |
| Colorectal | 4 (7%) |
| Neuroendocrine | 3 (6%) |
| Pancreatic | 3 (6%) |
| Gynaecological | 2 (4%) |
| Ovarian | 1 (2%) |
| Endometrial | 1 (2%) |
| Cholangiocarcinoma | 1 (2%) |
Data are median (IQR) and n (%). NSCLC=non-small-cell lung cancer.
*
Patient might have received multiple or combination therapies, resulting in the sum of previous treatments being >100%.
†
Patients with baseline CNS metastases.
‡
Subtypes of soft tissue sarcoma included cervical adenosarcoma (n=1), dedifferentiated chondrosarcoma (n=1), endometrial stromal sarcoma (n=1), follicular dendritic cell sarcoma (n=1), gastrointestinal stromal tumour (n=1; wild-type gastrointestinal stromal tumour, succinate dehydrogenase complex subunit B immunohistochemistry—tumour cells retain normal expression), malignant peripheral nerve sheath tumour (n=1), and sarcoma not otherwise specified (n=7).